Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. [electronic resource]
Producer: 20100528Description: 477-83 p. digitalISSN:- 1555-905X
- Administration, Oral
- Adult
- Age Factors
- Aged
- Antineoplastic Agents -- administration & dosage
- Blood Pressure -- drug effects
- Carcinoma -- drug therapy
- Chi-Square Distribution
- Female
- Humans
- Hypertension -- chemically induced
- Middle Aged
- Neoplasm Recurrence, Local
- Ovarian Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Proteinuria -- chemically induced
- Quinazolines -- administration & dosage
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Risk Assessment
- Risk Factors
- Severity of Illness Index
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.